Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Axsome Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Axsome Therapeutics, Inc.’s stock price such as:

• Axsome Therapeutics, Inc.’s current stock price and volume
• Why Axsome Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for AXSM from analysts
• AXSM’s stock price momentum as measured by its relative strength

About Axsome Therapeutics, Inc. (AXSM)

Before we jump into Axsome Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.

Want to learn more about Axsome Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Axsome Therapeutics, Inc..

Axsome Therapeutics, Inc.’s Stock Price as of Market Close

As of April 28, 2026, 4:00 PM, CST, Axsome Therapeutics, Inc.’s stock price was $185.000.

Axsome Therapeutics, Inc. is down 1.28% from its previous closing price of $187.400.

During the last market session, Axsome Therapeutics, Inc.’s stock traded between $181.665 and $190.100. Currently, there are approximately 50.63 million shares outstanding for Axsome Therapeutics, Inc..

Axsome Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Axsome Therapeutics, Inc. Stock Price History

Axsome Therapeutics, Inc.’s (AXSM) price is currently up 9.45% so far this month.

During the month of April, Axsome Therapeutics, Inc.’s stock price has reached a high of $193.490 and a low of $165.170.

Over the last year, Axsome Therapeutics, Inc. has hit prices as high as $193.490 and as low as $96.090. Year to date, Axsome Therapeutics, Inc.’s stock is up 1.29%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Axsome Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 28, 2026, there was 1 analyst who downgraded Axsome Therapeutics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Axsome Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Axsome Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Axsome Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Axsome Therapeutics, Inc. (AXSM) by visiting AAII Stock Evaluator.

Relative Price Strength of Axsome Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 28, 2026, Axsome Therapeutics, Inc. has a weighted four-quarter relative price strength of 7.27%, which translates to a Momentum Score of 76 and is considered to be Strong.

Want to learn more about how Axsome Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Axsome Therapeutics, Inc. Stock Price: Bottom Line

As of April 28, 2026, Axsome Therapeutics, Inc.’s stock price is $185.000, which is down 1.28% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Axsome Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.